Mecasermin

Mecasermin

Mecasermin

Pharmaceutical drug

Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[3][4][5]

Quick Facts Clinical data, Trade names ...

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[3]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[6] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[6]

References

  1. [1]
    https://www.tga.gov.au/resources/auspmd/increlex
  2. [2]
    "Summary Basis of Decision (SBD) for Increlex". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  3. [3]
    "Increlex- mecasermin injection, solution". DailyMed. 7 May 2020. Retrieved 30 May 2022.
  4. [4]
    Fintini D, Brufani C, Cappa M (June 2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
  5. [5]
    "Increlex". Drugs.com. Retrieved 10 January 2010.
  6. [6]
    "Iplex (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration.
Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Mecasermin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.